Amantadine in cancer fatigue

Evaluation of Amantadine efficacy compared to placebo in the treatment of cancer-related fatigue: a randomized, double-blind clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181208041882N10

Enrollment

Registered

2023-10-10

Start date

2022-05-09

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue due to cancer.

Interventions

Intervention 1: Intervention group: Intervention group: Cancer patients use amantadine hydrochloride 100 mg capsules(Amin company) orally twice a day for 6 weeks. Intervention 2: Control group: Cancer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients who complain of fatigue as a side effect of treatment Patients currently on a chemotherapy regimen are at risk for fatigue

Exclusion criteria

Exclusion criteria: Patients with a hemoglobin level of less than 10 g / dl Patients with a white blood cell count of less than 3,000 cells / mcl Patients with a platelet count less than 10,000 cells / mcl Patients with a serum creatinine greater than 2 mg / dl Patients whose bilirubin level is 1.5 times normal and their alkaline phosphatase and SGOT levels are more than 3 times normal Patients with melanoma

Design outcomes

Primary

Measure	Time frame
Evaluation of fatigue severity. Timepoint: Weeks 0, 1, 2, 3, 4, 5 and 6. Method of measurement: Questionnaire (Cancer-Related Fatigue Scale).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Heydari

Yazd University of Medical Sciences

b.heydari@ssu.ac.ir+98 35 3820 3410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026